A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer

This research study is currently not recruiting patients.

See other Malignant Neoplasm Of Prostate Research Studies

A Randomized Phase II Trial of Hypofractionated Radiotherapy for Favorable Risk Prostate Cancer

Study Overview

his randomized phase II trial studies radiation therapy to see how well it works in treating patients with prostate cancer.

Study Description

The purpose of this study is to demonstrate that 1-year health-related quality of life (HRQOL) for at least one hypofractionated arm is not significantly lower than baseline as measured by the Bowel and Urinary domains of the Expanded Prostate Cancer Index Composite (EPIC) instrument.

Research Study Identifier: TX2472

ClinicalTrials.gov Identifier: NCT1204008432 (RTOG0938)

Principal Investigator: Peter Johnstone

Not Recruiting

Contact the research team to learn more about this study.

Your Email

Not a valid e-mail address

Please Provide Email Address

First Name

Last Name

First name is mandatory

Your Phone

Please provide phone number

Invalid phone number

Valid phone number

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.

Last Updated: Jan 24, 2019

Recruitment Status: Closed